VANCOUVER, British Columbia, Sept. 7, 2012 /PRNewswire/ -- Del Mar Pharmaceuticals today announced that Jeffrey A. Bacha, President & Chief Executive Officer, will present at the 14th Annual Rodman & Renshaw Healthcare Conference on September 11th at the Waldorf Astoria Hotel in New York City.
Presentation Details
- Date: Tuesday, Sep 11, 2012
- Time: 4.30 4.55 PM
- Location: Waldorf Astoria Hotel, Starlight South
About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
For further information, please visit www.delmarpharma.com
or contact Jeffrey A. Bacha, President & CEO +1 (604) 629-5989
SOURCE Del Mar Pharmaceuticals
